PANA Share Price | Nuvation Bio, Inc. Stock Analysis & Recommendation

Q: How big is Nuvation Bio, Inc.?

Market Cap: As of Jun 18, Nuvation Bio, Inc. has a market capitalization of 581.85 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Nuvation Bio, Inc. reported net sales of 10.96 million and a net profit of -606.39 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 463.79 million and total assets of 540.63 million.

Q: What does Nuvation Bio, Inc. do?

Overview: Nuvation Bio, Inc. is a biotechnology company focused on identifying and acquiring opportunities within the pharmaceuticals and biotechnology sector, categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -53 Million (Quarterly Results - Mar 2025) Market cap: USD 581.85 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.08 Return on Equity: -43.17% Price to Book: 1.39Contact Details: Address: 357 Tehama Street, Floor 3, SAN FRANCISCO CA: 94103 Tel: 1 415 7543517 Fax: 1 302 6365454 Website: https://panacea.ecor1cap.com/

Q: Is Nuvation Bio, Inc. overvalued or undervalued?

As of 5 August 2024, the valuation grade for Nuvation Bio, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 2.01 and an EV to Sales ratio of 35.57, which are considerably high for a company in the pharmaceuticals and biotechnology sector. Additionally, the negative ROE of -43.17% further underscores the challenges the company faces.In comparison to its peers, Nuvation Bio, Inc. has a worse EV to EBITDA ratio of -1.90 compared to uniQure NV's -6.6289, highlighting its relative inefficiency. The stock has experienced mixed performance, with a year-to-date return of 19.17%, outperforming the S&P 500's 12.22%, but it has significantly lagged over longer periods, with a 5-year return of -71.18% compared to the S&P 500's 96.61%. This performance suggests that while there may be short-term gains, the long-term outlook remains concerning.

Q: Is Nuvation Bio, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Nuvation Bio, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. Daily moving averages also support a bullish stance. However, the monthly KST is mildly bearish, and the Dow Theory shows no trend on a weekly basis while being mildly bullish monthly. In terms of performance, the stock has returned 19.17% year-to-date, outperforming the S&P 500's 12.22%, but has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish with moderate strength.

Results Declared: Nuvation Bio, Inc. has declared results on 04 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

983.78 k

Shareholding (Mar 2026)

FII

13.12%

Held by 86 FIIs

DII

46.14%

Held by 56 DIIs

Promoter

12.30%

How big is Nuvation Bio, Inc.?

22-Jun-2025

As of Jun 18, Nuvation Bio, Inc. has a market capitalization of 581.85 million, categorizing it as a Micro Cap company, with net sales of 10.96 million and a net profit of -606.39 million over the latest four quarters.

View full answer

What does Nuvation Bio, Inc. do?

22-Jun-2025

Nuvation Bio, Inc. is a micro-cap biotechnology company focused on opportunities in the pharmaceuticals sector, with recent net sales of $3 million and a net loss of $53 million. The company has a market cap of $581.85 million and does not currently pay dividends.

View full answer

Is Nuvation Bio, Inc. overvalued or undervalued?

20-Sep-2025

As of August 5, 2024, Nuvation Bio, Inc. is considered risky due to overvaluation and poor financial metrics, including a Price to Book Value of 2.01, an EV to Sales ratio of 35.57, and a negative ROE of -43.17%, despite a year-to-date return of 19.17% that outperformed the S&P 500.

View full answer

Is Nuvation Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Nuvation Bio, Inc. shows a bullish technical trend with positive momentum indicators, having returned 19.17% year-to-date, outperforming the S&P 500, despite underperforming over longer periods.

View full answer

Compare Nuvation Bio, Inc. with Similar Stocks

MeiraGTx Holdings Plc Zura Bio Ltd.23andMe Holding Co.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared Negative results for the last 4 consecutive quarters

INTEREST(HY) At USD 0.47 MM has Grown at 259.85%
OPERATING CASH FLOW(Y) Lowest at USD -168.19 MM
OPERATING PROFIT(Q) Lowest at USD -63.23 MM

Risky - Negative EBITDA

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,564 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-66.48%

Price to Book

4.80

Revenue and Profits:

Net Sales:

83 Million

(Quarterly Results - Mar 2026)

Net Profit:

5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.96%

6 Months

1.27%

1 Year

128.1%

2 Years

48.76%

3 Years

195.68%

4 Years

6.21%

5 Years

-58.53%

Nuvation Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

129.52%

EBIT Growth (5y)

-211.19%

EBIT to Interest (avg)

-104.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.08

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

77.14%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.80

EV to EBIT

-5.24

EV to EBITDA

-5.27

EV to Capital Employed

-67.86

EV to Sales

45.62

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-66.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 44 Schemes (28.43%)

Foreign Institutions

Held by 86 Foreign Institutions (13.12%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 2,583.87% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 110.15% vs -259.46% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "83.20",
          "val2": "3.10",
          "chgp": "2,583.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.40",
          "val2": "-58.70",
          "chgp": "107.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.70",
          "val2": "0.10",
          "chgp": "6,600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.90",
          "val2": "-0.80",
          "chgp": "462.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.40",
          "val2": "-53.20",
          "chgp": "110.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.60%",
          "val2": "-19,132.30%",
          "chgp": "1,917.89%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 696.20% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 63.97% vs -649.21% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "62.90",
          "val2": "7.90",
          "chgp": "696.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-211.30",
          "val2": "-166.90",
          "chgp": "-26.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "13.70",
          "val2": "0.30",
          "chgp": "4,466.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-426.00",
          "chgp": "99.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-204.60",
          "val2": "-567.90",
          "chgp": "63.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,387.20%",
          "val2": "-21,282.50%",
          "chgp": "1,789.53%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

83.20

3.10

2,583.87%

Operating Profit (PBDIT) excl Other Income

4.40

-58.70

107.50%

Interest

6.70

0.10

6,600.00%

Exceptional Items

2.90

-0.80

462.50%

Consolidate Net Profit

5.40

-53.20

110.15%

Operating Profit Margin (Excl OI)

46.60%

-19,132.30%

1,917.89%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 2,583.87% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 110.15% vs -259.46% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

62.90

7.90

696.20%

Operating Profit (PBDIT) excl Other Income

-211.30

-166.90

-26.60%

Interest

13.70

0.30

4,466.67%

Exceptional Items

-0.80

-426.00

99.81%

Consolidate Net Profit

-204.60

-567.90

63.97%

Operating Profit Margin (Excl OI)

-3,387.20%

-21,282.50%

1,789.53%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 696.20% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 63.97% vs -649.21% in Dec 2024

All Annual Results

Company CV

About Nuvation Bio, Inc.

Nuvation Bio, Inc.

Pharmaceuticals & Biotechnology

Panacea Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company is focused on identifying and acquiring opportunity within the biotechnology sector.

Company Coordinates

Company Details

357 Tehama Street, Floor 3 , SAN FRANCISCO CA : 94103

Tel: 1 415 7543517

https://panacea.ecor1cap.com/

Registrar Details